Patients, n (%)
|
Apremilast-exposure period*
|
---|
Weeks 0 to ≤ 52
|
Weeks > 52 to ≤ 104
|
Weeks > 104 to ≤ 156
|
Weeks > 156 to ≤ 208
|
Weeks > 208 to ≤ 260
|
---|
30 mg twice daily (n = 721)
|
20 mg twice daily (n = 720)
|
30 mg twice daily (n = 520)
|
20 mg twice daily (n = 508)
|
30 mg twice daily (n = 443)
|
20 mg twice daily (n = 422)
|
30 mg twice daily (n = 401)
|
20 mg twice daily (n = 366)
|
30 mg twice daily (n = 364)
|
20 mg twice daily (n = 320)
|
---|
Nausea
|
16 (2.2)
|
8 (1.1)
|
0 (0.0)
|
0 (0.0)
|
0 (0.0)
|
0 (0.0)
|
0 (0.0)
|
0 (0.0)
|
0 (0.0)
|
0 (0.0)
|
Diarrhea
|
15 (2.1)
|
6 (0.8)
|
1 (0.2)
|
0 (0.0)
|
0 (0.0)
|
1 (0.2)
|
0 (0.0)
|
0 (0.0)
|
1 (0.3)
|
0 (0.0)
|
Headache
|
11 (1.5)
|
4 (0.6)
|
0 (0.0)
|
0 (0.0)
|
1 (0.2)
|
0 (0.0)
|
0 (0.0)
|
0 (0.0)
|
0 (0.0)
|
0 (0.0)
|
Vomiting
|
6 (0.8)
|
1 (0.1)
|
0 (0.0)
|
0 (0.0)
|
0 (0.0)
|
0 (0.0)
|
0 (0.0)
|
0 (0.0)
|
0 (0.0)
|
0 (0.0)
|
Dizziness
|
4 (0.6)
|
2 (0.3)
|
0 (0.0)
|
0 (0.0)
|
0 (0.0)
|
0 (0.0)
|
0 (0.0)
|
0 (0.0)
|
0 (0.0)
|
0 (0.0)
|
Upper abdominal pain
|
3 (0.4)
|
4 (0.6)
|
0 (0.0)
|
0 (0.0)
|
0 (0.0)
|
0 (0.0)
|
0 (0.0)
|
1 (0.3)
|
0 (0.0)
|
0 (0.0)
|
Migraine
|
3 (0.4)
|
1 (0.1)
|
0 (0.0)
|
0 (0.0)
|
0 (0.0)
|
0 (0.0)
|
0 (0.0)
|
0 (0.0)
|
0 (0.0)
|
0 (0.0)
|
Fatigue
|
3 (0.4)
|
2 (0.3)
|
0 (0.0)
|
0 (0.0)
|
0 (0.0)
|
0 (0.0)
|
0 (0.0)
|
1 (0.3)
|
0 (0.0)
|
0 (0.0)
|
- *Includes all patients who received apremilast during the time interval relative to the start of apremilast treatment